Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Zoetis ( (ZTS) ) has provided an announcement.
Zoetis announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, showcasing its exemplary 2024 performance and strategic growth initiatives. The company reported double-digit revenue growth, driven by market-leading products and an innovative pipeline poised to sustain above-market growth. Zoetis continues to capitalize on industry trends like the human-animal bond and increasing pet medicalization, positioning itself for future success with strategic investments and shareholder value creation.
More about Zoetis
Zoetis Inc. operates in the animal health industry, providing a diverse portfolio of products and solutions primarily focused on pharmaceuticals, vaccines, and diagnostic products for both companion animals and livestock. The company is recognized for its deep industry engagement and innovation-driven approach, serving a global market with a strong emphasis on sustainable agriculture and advancing animal health.
YTD Price Performance: 0.44%
Average Trading Volume: 2,473,433
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $73.68B
For a thorough assessment of ZTS stock, go to TipRanks’ Stock Analysis page.
